MedTrace Logo

A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy

NCT07541287 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-21

No results posted yet for this study

Summary

This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.

Conditions

Interventions

DRUG

JADE101

JADE101 is supplied as sterile solution to be administered by SC injection

Sponsors & Collaborators

  • Jade Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Li Li, MD · Jade BioSciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-01-31
Completion
2029-04-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07541287 on ClinicalTrials.gov